General presentation

1,163 views

Published on

Published in: Health & Medicine, Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,163
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
6
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

General presentation

  1. 1. Nancy Fischer Contents Pharma Campaign Branding.......................................... 1- 4 Magazine Advertising................................................... 5- 6 Website Design . . .......................................................... 7- 8 Accounting Firm/Banks . . .............................................. 9 -12 Annual Reports.......................................................... 13-14 Marketing Kit. . ............................................................... 15 Packaging..................................................................... 16 Powerpoint presentations............................................... 17 Logo and Icon Design.. ................................................... 18
  2. 2. Diprospan® Concepts and Final Brochure Campaign Branding 1 For pa in du e t o inF l a mmation , Diprospan ® prospan ® 24 to 48 Hours postinjection injection Local anesthe ic gives mmed ate re ief by mask ng pain 4 to 8 Hours pos injection 24 to 48 Hours pos injection Anes het c wears o f and pain may eturn L ng-act ng cort cos ero ds may begin to prov de el ef of pa n only diprospan® beg ns to reduce inflammation with n 1 to 2 hours prov des long lasting relief Fast aCtinG Betamethasone sodium phosphate begins to reduce inflammation within 1 to 2 hours before anes he ic wears o f s Long La ting ReLief Betamethasone acetate p ovides sustained relief Celestone® Soluspan® indication The intra articular or soft tissue administ ation of CELESTONE® SOLUSPAN® Injectable Suspension is indicated as adjunctive therapy for short term administ ation (to ide he patient over an acute episode or exacerba ion) in acute gouty ar hri is acute and subacute bur s tis acute nonspec fic tenosynov tis epicondy itis rheumatoid arthr tis synovi is of osteoar h itis Important Safety Informa ion As w th any potent corticosteroid adverse events have been associated w th CELESTONE® SOLUSPAN® including flu d and electro lyte disturbances as we l as adve se reactions involving the following systems a lergic reactions cardiovascular dermatologic endocrine gast ointestinal metabolic musculoskeletal neurological/psychiatric and ophthalmic Corticosteroids may also affect immune response CELESTONE® SOLUSPAN® should not be administered intravenously or used in systemic fungal infections Vaccination administration of live or ive attenuated vaccines is contraindicated in patients eceiving immunosupp essive doses of corticosteroids Please see accompanying fu l P esc ibing Informa ion W I D E LY AVA I L A B L E d lonG last nG W I D E LY AVA I L A B L E Long L ing R Lie Design and create three concepts. Client chose solution and designed layed out and produced final solution. Models were selected and managed in photoshoot. ONLY Diprospan ONLY Diprospan Fast relief ...that lasts The ONLY injectable corticosteroid product with a unique dual-agent formulation Betamethasone sodium phosphate provides fast onset of action Betamethasone acetate provides sustained relief Proven safe and effective, with over 40 years of clinical experience When the pain of inflammation demands fast relief... ONLY Diprospan begins to reduce inflammation in 1-2 hours before anesthetic wears off Ava lable in a multi-dose 5-mL vial Other long-acting corticosteroids Inject on Inject on Anesthet c Anesthetic Betamethasone Sodium Phosphate 1 2 hrs hrs REL EF PAIN PAIN Betamethasone Acetate Inject on Fast relief that lasts. Betamethasone Long Act ng Co ticosteroid Betamethasone sodium phosphate aceta e Anesthetic gives mmediate Begins to reduce Provides rel ef by masking inflammation in sustained relief pain 1 2 hours before anesthet c wears off Inject on Pain In 4 8 hours Anesthetic gives immediate post injection rel ef by masking pa n returns pain Long Act ng Cort cos eroid Beg ns to work 24 48 hours post in ect on Fast relief that lasts.
  3. 3. Campaign Branding 2 Elecon® Branding Concepts AVOID THE STRUGGLE BETWEEN EFFICACY AND SAFETY FOR EFFICACY AND SAFETY TOGETHER CHOOSE ELOCON Efficacy and safety go better together. Efficacy and safety tied together NO NEED TO CHOOSE YOUR DIRECTION WITH ELECON IT’S CLEAR (side effects) ( e f f i c a cy ) LESS IS MORE This concept needs a tagiline. The s mple steroid choice for efficacy + safety Concepts and designs for rebranding of the. Elecon® campaign. Worked with writers to come up with strategic ideas.
  4. 4. Campaign Branding 3 Puregon® Concepts and Final Solution Puregon Delivers The Proof is in the Numbers The proof is in the numbers Proven efficacy in the largest IVF clinical trial ever conducted. • Proven results 38% ongoing pregnancy rate • Exce lent pregnancy rates regardless of endogenous LH levels • Optimal dosing flexibi ity patient friendly device • Rich heritage of qua ity and innovation Proven efficacy in the largest IVF clinical trial ever conducted. 38% Proven efficacy in world’s largest IVF clinical trial • Proven results 38% ongoing pregnancy rate • Proven results 38% ongoing pregnancy rate • Exce lent pregnancy rates regardless of • Excellent pregnancy rates regardless of endogenous LH levels • Optimal dosing flexibi ity patient friendly device • Rich heritage of qua ity and innovation A million successes and counting. endogenous LH levels A million successes and counting. • Optimal dosing flexib lity patient friendly device • Rich heritage of quality and innovation Living Proof Proven efficacy in the largest IVF clinical trial ever conducted. • Proven resu ts – 38% ongoing pregnancy rate Excellent pregnancy rates regardless of endogenous LH levels Optimal dosing flexibi ity, patient friendly device • Rich her tage of quality and innovation Proven results. Powerful heritage. A m llion successes and counting Assuring the Donovan Family Tree Lives On Proven efficacy in the largest IVF clinical trial ever conducted. Proven resu ts 38% ongoing pregnancy rate Excellent pregnancy rates regardless of endogenous LH levels Optimal dosing flex bility, patient friendly device Rich her tage of quality and innovation Giving Life to a New Generation. Design and create concepts. Took clients chosen selection and created full campaign.
  5. 5. Brochure www.FertilityJourney.com Wherever you are in your journey towards building a family – whether you’ve just begun or are almost there – you’ll find guidance, support, and resources to help you make decisions along the way Fertility Journey ™ Brochure 4 Are you Trying to Get Pregnant? Now you can find the information and support you need in one place: www.FertilityJourney.com www.FertilityJourney.com is brought to you by Schering-Plough over lityJourney.com parenthood is an easy one But for nearly one in six American women, getting pregnant takes longer — with twists, turns and sometimes roadblocks along the way For couples encountering problems, FertilityJourney com can be a l feline of information, support, and guidance Copyright © 2009 Sche ing Corpora ion Kenilwor h NJ 07033 A l r ghts reserved Pr nted in USA FQ0106 8/09 Design new layouts of brochure for Fertility Journey™. Layouts were then applied to refresh all other collateral including pop-up banners. FertilityJourney.com is a free resource for comprehensive information, guidance, and support during your journey to parenthood. If You Are Thinking About Getting Pregnant If you’re considering getting pregnant or are ready to start trying, these are exciting times! FertilityJourney.com is a Web site that can help you and your partner prepare for a healthy conception and pregnancy, and recognize if it’s time to look for help You’ll find information such as: • How to decide whether you’re ready • Truths and myths about preconception FertilityJourney com can help you take an active approach to achieving pregnancy, and making informed choices On the Web site you’ll find in-depth information including: • How to boost your chances of getting pregnant • How to know when it’s time to seek help • The pre-pregnancy check-up • Getting pregnant in later years You’ll also find specialized interactive tools including: • A 30-second fertility quiz • An ovulation calculator to help you figure out when you’re most fert le • A ready-to-get-pregnant checklist • How to find and choose a fertility doctor • How fert lity tests are conducted, and what they mean • How to make the most of your insurance coverage and find ways to pay for treatment • How to deal w th difficult emotions and stress a persona ized newsletter program that supports you through the steps of your fertility journey You and your partner wi l benefit from relevant information that's appropriate for you, delivered monthly to your e-mail inbox • Use the Clinic Locator to find a specia ist in your area • Download Guidebooks for in-depth explorations of current treatments and fertility technologies, support information, glossaries of common terms – even a place to chart your treatment cycles • Stay up-to-date with breaking news about fertility and treatment { Visit Today Take the first step on your journey to take advantage of all the benefits of FertilityJourney.com. }
  6. 6. National Ad Campaign fe of a NuvaRing® Advertising Consumer Magazine (part 1) NuvaRing® Woman and a muffin on the way to the office. at her desk. The gym after work. Out to dinner her boyfriend. Her days are full. No time to y about daily birth control. What to do? hecks out www.nuvaring.com to find out about ething different. Interesting. NuvaRing® is a low-dose onthly birth control she can count on. She discovers that it’s safe, 99% effective, and convenient. When used as directed, causes ittle or no breakthrough bleeding, She asks her doctor ® about NuvaRing . Because less time thinking about birth control means more time to liv h lif Who’s NOT THINKING About BIRTH CONTROL Every Day? You’d Be SURpRISED! Find out about surprisingly simple birth control at NuvaRing.com Go to www.nuvaring.com to find out how you can stop worrying about birth control every day. And ask your doctor if NuvaRing® is right for you. is just effective as a small, comfortable • NuvaRing isthat delivers a low dose • NuvaRing used asasdirected, but the pill, when vaginal ring of hormones. Important Safety Information The use of comb nat on oral cont acept ves s assoc a ed wi h increased rsks of several seri s de effects nclud ng blood clots which may lead to s roke or heart attack NuvaR ng® is n for women wi h a his o y of hese condi ions The risk of gett ng blood clots may be g eate w th the ype of proge tin n NuvaRing® than w th some other progest ns in cer ain low dose bir h con rol p lls It is unknown if the isk of blood clo s s different w th NuvaRing® use than w th the use of certa n birth cont ol p lls Cga ette mokng ncreases the isk of serous card ovascular s de effects especially n women over 35; women who use comb na ion hormonal con racep ives a e st ongly adv sed not to moke NuvaR ng® s not for women w th certa n cance s or those who may be pregnant NuvaR ng® does not protect aga n t HIV nfection and other sexually transmi ted diseases The most common s de effects repor ed by NuvaRing® users are: vagnal nfections and i rtation vagnal sec e ion headache weight gain and nausea Please see next page for addi ional mportant pa ient nformation You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www fda.gov/medwatch, or call 1 800 FDA 1088. Learn the facts about once-a-month NUVARING® at nuvaring.com NuvaRing ® is approved for the prevention of pregnancy in women. Important Safety Information The use of combination oral cont aceptives is associated with increased isks of several serious side effects, including blood clots, which may lead to st oke or heart attack NuvaRing® is not for women wi h a his ory of these conditions The isk of getting blood clots may be greater with the ype of progestin in NuvaRing® than with some other p ogestins in certain low dose birth cont ol pills It is unknown if the risk of blood clots is d fferent with NuvaRing® use han with the use of certain birth control p lls Ciga e te smoking increases he risk of serious cardiovascular side effects, especially in women over 35; women who use combination hormonal contracep ives are strongly advised not to smoke NuvaRing® is not for women with cer ain cance s or those who may be pregnant NuvaRing® does not protect against HIV infection and other sexually ransmitted diseases The most common side effects reported by NuvaRing® users are vaginal infections and ir itation, vaginal sec e ion, headache, weight gain, and nausea Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Copyright © 2009 S hering Co pora i n Ken lwo th NJ 07033 A l rights ese ved P in ed in USA NV0130 12/09 NUVARING® LESS TO REmEmBER. ® vaginal ring that delivers a low dose of hormones. • NuvaRing is just as effective as the pill, ® when used as directed, but you dont have to take it everyday. NuvaRing®– It Fits You NuvaRing® is approved for the prevention of pregnancy in women. Important Safety Information The use of combination oral contraceptives is associa ed with inc eased risks of several serious side effects, including blood clots, which may lead to s roke or heart attack NuvaRing® is not for women with a history of these conditions The risk of getting blood clots may be greater with the type of progestin in NuvaRing® than with some other progestins in certain low dose bir h control pi ls It is unknown f the risk of blood clots is diffe ent with NuvaRing® use than wi h the use of certain birth cont ol pills Cigarette smoking increases the risk of serious cardiovascular side effects, especially in women over 35; women who use combination ho monal con raceptives are st ongly advised not to smoke NuvaRing® is not for women with certain cancers or hose who may be pregnant NuvaRing® does not p otect against H V infection and other sexually transmi ted diseases The most common side effects eported by NuvaRing® users are vaginal infections and irri ation, vaginal secretion, headache, weight gain, and nausea Please see next page for additional important patient info mation. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda gov/medwatch, or call 1-800-FDA-1088. Copyright © 2009 Sche ing Co po ation Ken lwo th NJ 0 033 A l righ s re erv d P i ted in USA NV0130 12/ 9 NUVARING® LESS TO REmEmBER. NuvaRing®— Monthly Birth Control... So You Have Less to Forget NuvaRing®— Monthly Birth Control... So You Have Less to Forget • NuvaR ng is a sma l comfortab e vaginal • NuvaRing is a small ® ring that delivers a low dose of hormones comfortable vaginal ring that delivers a low dose of hormones • NuvaR ng is just as effect ve as the p ll when used as directed but you don’t have to take it everyday • NuvaRing is just as ® effective as the pi l when used as directed but you don’t have to take it everyday you don’t have to take it everyday. Please see next page for add tional important patient information. You are encouraged to report negative side effects of prescription drugs to the FDA. Copy ight © 2 09 Sch ring C rpo ation K nilworth NJ 07033 A l righ s es rved Print d in U A NV 130 12 09 Choose safe & effective monthly NuvaRing® • NuvaRing is a small, comfortable ® ® NuvaRing® is approved for the prevention of pregnancy in women. FORGET DAILy BIRTH CONTROL! NOW yOU HAVE A DIFFERENT CHOICE. Step out of your daily birth control routine. Find out more at www.nuvaring.com Step out of your daily birth control routine. Find out more at www.nuvaring.com Who’s NOT THINKING About BIRTH CONTROL Every Day? You’d Be SURpRISED! Find out about surprisingly simple birth control at NuvaRing.com is just effective as a small, comfortable • NuvaRing isthat delivers a low dose • NuvaRing used asasdirected, but the pill, when vaginal ring ® ® NuvaRing® is approved for the prevention of pregnancy in women. Important Safety Information The use of combina ion oral contraceptives is associated with increased risks of several se ious side effects, including blood clots, which may lead o stroke or heart attack NuvaRing® is not for women with a history of these conditions The risk of getting blood clo s may be grea er with the type of p oges in in NuvaRing® than wi h some o her progestins in ce tain low dose birth control pi ls It is unknown f he risk of blood clots is diffe ent with NuvaRing® use than with the use of certain birth con rol pi ls Cigarette smoking inc eases the risk of se ious cardiovascular side effects, especia ly in women over 35; women who use combination hormonal contraceptives are s rongly advised not to smoke NuvaRing® is not for women with certain cancers or those who may be pregnant NuvaRing® does not pro ect against H V infec ion and other sexually transmitted diseases The most common side effects reported by NuvaRing® users are vaginal infections and irritation, vaginal secretion, headache, weight gain, and nausea Please see next page for additional important patient information. You are encouraged to report negative side effects of prescription drugs to the FDA. NuvaRing® is approved for the prevention of pregnancy in women. Important Safety Information The use of combination oral cont aceptives is associated with increased isks of several serious side effects, including blood clots, which may lead to st oke or heart attack NuvaRing® is not for women wi h a his ory of these conditions The isk of getting blood clots may be greater with the ype of progestin in NuvaRing® than with some other p ogestins in certain low dose birth cont ol pills It is unknown if the risk of blood clots is d fferent with NuvaRing® use han with the use of certain birth control p lls Ciga e te smoking increases he risk of serious cardiovascular side effects, especially in women over 35; women who use combination hormonal contracep ives are strongly advised not to smoke NuvaRing® is not for women with cer ain cance s or those who may be pregnant NuvaRing® does not protect against HIV infection and other sexually ransmitted diseases The most common side effects reported by NuvaRing® users are vaginal infections and ir itation, vaginal sec e ion, headache, weight gain, and nausea Please see next page for additional important patient information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Copy ight © 2 09 Sch ring C rpo ation K nilworth NJ 07033 All igh s re er ed Printed in USA NV01 0 12 09 Copyright © 2009 S hering Co pora i n Ken lwo th NJ 07033 A l rights ese ved P in ed in USA NV0130 12/09 of hormones. you don t have to take it everyday. NuvaRing ® is approved for the prevention of pregnancy in women. Important Safety Information The use of combination oral contraceptives is associa ed with inc eased risks of several serious side effects, including blood clots, which may lead to s roke or heart attack NuvaRing® is not for women with a history of these conditions The risk of getting blood clots may be greater with the type of progestin in NuvaRing® than with some other progestins in certain low dose bir h control pi ls It is unknown f the risk of blood clots is diffe ent with NuvaRing® use than wi h the use of certain birth cont ol pills Cigarette smoking increases the risk of serious cardiovascular side effects, especially in women over 35; women who use combination ho monal con raceptives are st ongly advised not to smoke NuvaRing® is not for women with certain cancers or hose who may be pregnant NuvaRing® does not p otect against H V infection and other sexually transmi ted diseases The most common side effects eported by NuvaRing® users are vaginal infections and irri ation, vaginal secretion, headache, weight gain, and nausea Please see next page for additional important patient information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda gov/medwatch, or call 1-800-FDA-1088. Copyright © 2009 Sche ing Co po ation Ken lwo th NJ 0 033 A l righ s re erv d P i ted in USA NV0130 12/ 9 5 Concepts for ad campaign. Working writer and creative director on rebranding print, television and miscellaneous collateral.
  7. 7. National Ad Campaign 6 NuvaRing® Advertising Consumer Magazine (Part 2) No Birth Control Pills to Remember... or Forget! Break Free From the Pack With Once-A-Month NuvaRing® No Birth Control Pills to Remember... or Forget! Some women find day to day birth control okay But if that pack mentality doesn t work for you try NuvaRing® NuvaRing® is not a da ly pill It s a small comfortab e vag nal ring you put in once a month and remove after 3 weeks or a full month of pregnancy prevent on NuvaRing® del vers a continuous ow Break Free From the Pack With Once-A-Month NuvaRing® Some women find day to day birth control okay But if that pack mental ty doesn t work for you try NuvaRing® NuvaRing® is not a daily p ll t s a sma l comfortable vaginal r ng you put n once a month and remove after 3 weeks for a full month of pregnancy prevention NuvaRing® delivers a continuous low dose of hormones When used as dose of hormones When used as directed it s as effective as the pi l but directed it s as effect ve as the pill but you don t have to take t every day you don t have to take it every day So say goodbye to the o d song and So say goodbye to the old song and dance and say hello to NuvaRing® dance and say he lo to NuvaRing® NuvaR ng® is approved for the p evention of pregnancy n women. Important Safety Informat on The use of combination oral contracep ives is assoc ated with increa ed isks of several serious side effects ncluding blood clots wh ch may lead to stroke or heart at ack NuvaR ng® is not for women with a his ory of these condit ons The risk of gett ng blood clots may be greater w th the type of proges in in NuvaRing® than with some other p ogestins in certain low dose b rth con rol pi ls It is unknown f the r sk of blood clots is different with NuvaRing® use han wi h the use of certain birth control p lls Cigarette moking increases the r sk of ser ous cardiovascular NuvaR ng® is approved for he prevention of pregnancy n women. side effects espec a ly n women over 35; women who use combination ho monal contracep ives are s rongly advised not to smoke NuvaR ng® s not for women w th certain cancers or those who may be pregnant NuvaRing® does not protect aga nst H V nfection and other sexua ly ransmi ted d seases The most common side effects reported by NuvaR ng® users a e: vag nal infections and irr tation vaginal secret on headache weight ga n and nausea Ask your doctor if prescription NuvaRing® is right for you, or for more information visit www.nuvaring.com. Important Safety nformation The use of combination oral contracep ives s assoc ated with increased isks of several serious s de effec s ncluding blood clots wh ch may lead to st oke or heart at ack NuvaR ng® s not for women with a h story of these condi ions The r sk of get ing blood clots may be greater with the type of proges in in NuvaR ng® than with some other progest ns in certain low dose b rth con rol pi ls It is unknown f he isk of blood clots is d fferent with NuvaRing® use than w th the use of certain bir h control p lls C garette smoking ncreases the r sk of ser ous ca d ovascular ONce A MONth Please see next page for add tional mportant patient nfo mat on You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1 800 FDA 1088. Copyr ght © 2008 Scher ng Co pora ion Ken lwor h NJ 07033 A l rights reserved Pr nted in USA NV0099 side effects espec ally in women over 35; women who use comb nat on hormonal contraceptives are s rongly advised not to smoke NuvaRing® is not for women w th certain cancers or those who may be pregnant NuvaRing® does not protect against H V infection and other sexua ly ransm tted d sea es The most common side effects repor ed by NuvaRing® users a e: vag nal infect ons and ir itat on vaginal sec e ion headache weight ga n and nausea Ask your doctor if prescription NuvaRing® is right for you, visit www.nuvaring.com. ONce A MONth Please see next page for addit onal mportant patient nfo ma ion You are encouraged to report negative s de effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or ca l 1 800 FDA 1088. 10/08 Copyr ght © 2008 Sche ing Corpo a ion Ken lwo th NJ 07033 All r ghts reserved P inted n USA NV0099 10/08 No Birth Control Pills to Remember... or Forget! Once-Monthly Contraception hhhmmmm... Now That’s Got a Ring to It! Some women find day to day b rth control okay But f that pack Break Free From the Pack With Once-A-Month NuvaRing® Some women find day to day b rth control okay But f that pack mental ty doesn t work for you try NuvaR ng® NuvaRing® is not a dai y pill It s a sma l comfortable vaginal ring you put in once a month and remove after 3 weeks for a full month of pregnancy prevention mentality doesn t work or you try NuvaRing® NuvaRing® is not a daily NuvaRing® de ivers a continuous low p ll t s a small comfortable vaginal ring you put in once a month and dose of hormones When used as remove after 3 weeks or a full month of pregnancy prevent on directed t’s as effective as the p ll but you don’t have to take it every day NuvaRing® delivers a continuous low dose of hormones When used as directed t s as So say goodbye to the o d song and effect ve as the pill but you don t have to take it every day So say goodbye to the old song dance and say he lo to NuvaRing® and dance and say hello to NuvaRing® Ask your doctor if prescription NuvaRing is right for you, visit www.nuvaring.com. ® You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or ca l 1 800 FDA 1088. Important Safety nformation The use of combination oral contraceptives s associated wi h increased risks of seve al ser ous s de effects includ ng blood clots which may lead to stroke or heart attack NuvaRing® is not for women wi h a h story of hese cond tions The isk of get ing blood clots may be g ea er wi h the type of progest n in NuvaR ng® han wi h some other progestins n certain low dose b rth control p lls t s unknown if the risk of blood clo s is d ffe ent with NuvaRing® use than w th the use of certa n b rth con rol pi ls C garet e smok ng nc eases the risk of serious cardiovascular s de effec s especially in women over 35; women who use combinat on hormonal contraceptives a e strongly adv sed not o smoke NuvaR ng® s not for women with certa n cancers or those who may be pregnant NuvaR ng® does not p otect against HIV nfec ion and other sexua ly ransm tted diseases The most common side effects reported by NuvaRing® use s are: vaginal infections and rr tation vaginal ec e ion headache weight gain and nausea Please see next page for add tional mportant pat ent information ONce-A-MONth NuvaRing® is approved for the prevention of pregnancy in women Important Sa ety Information The use of comb na ion oral contraceptives is assoc a ed with increased r sks of several serious s de effects including blood clots which may ead to stroke or heart attack NuvaR ng® s not for women w th a hi tory of hese cond t ons The r sk of ge ting blood clots may be greater wi h the type of proges in n NuvaR ng® han w th some other proges ins n certain ow dose birth control pil s It is unknown f the risk of blood clots is d fferent wi h NuvaR ng® use than w th the use of cer a n birth cont ol pil s C ga e te smoking increases he isk of serious card ovascular s de effects espec ally in women over 35; women who use combination hormonal cont acept ves are st ongly advised not o smoke NuvaRing® is not for women wi h certain cancers or hose who may be pregnant NuvaR ng® does not protect against HIV n ec ion and other exual y transmi ted d seases The most common side effec s reported by NuvaR ng® users a e: vaginal n ec ions and irr tat on vag nal secret on headache weight gain and nausea Please see next page for addi ional important pat ent information You are encouraged to report negative side effects of prescript on drugs to the FDA Visit www fda gov/medwatch or call 1 800 FDA 1088 Copyr ght © 2008 Schering Corporat on Kenilworth NJ 07033 A l rights reserved Pr nted n USA NV0099 Concepts for ad campaign. Rebranding of print, television and miscellaneous collateral. 10 08 Copyr ght © 2008 Scher ng Co po ation Keni worth NJ 07033 All r gh s e e ved Pr nted n USA NV0099 10/08 Ask your doctor if prescription NuvaRing® is right for you, visit www.nuvaring.com. ONce A MONth
  8. 8. Web Banners / Digital Development Women’s Health, NuvaRing® and Celestone® Design for email blast campaign. Designed and created all artwork for banners. On these pop-up and web banners ensured files were seamless for usage. Designed interface for Women’s Health, comparative website for NuvaRing®. Created all banner and layout of content for these email blasts. 7
  9. 9. Web Development FX Concepts and Prolifics Websites 8 www.fx-concepts.com Redesigned entire website from the start to finish. Developed and presented concepts, created all layered artwork and worked with programmers to insure seamless graphics and navigation for user. www.prolifics.com Refreshed existing website. Developed and presented concepts to client. Created all layered artwork and worked with programmers to insure seamless graphics and navigation for user.
  10. 10. Conference Graphics KPMG Summer Shindig 9 MONTVALE’S Summer I ! SHINDOGY’S THE DAY! T DA Designed and developed final concept and artwork for Summer Shindig mer ! Sum DIG MO ’S VALE NT HIN S er mm IG! Su D MO ’S VALE NT HIN S ! HEF AC IT’S Montvale Café Monday, June 18 12:30 p.m. e Ther u ee Yo S Thursday, June 28 3:30 p.m. – 7:30 p.m.
  11. 11. Brochure Rebranded materials for AI Funds. Final was implemented and used for all new components. KPMG Collateral 10 The KPMG Difference 1 Helping You Navigate a Changing World: 2 Alternative Investments: An Overview KPMG’s Distinctive Approach to Alternative Investment Funds kpmg.com 3 Our Clients KPMG’s Alternat ve Investment Funds practice is comprised of audit, tax, and adv sory profess ona s w th deep knowledge of alternative investment products and the r sponsors includ ng: • Commod ty Poo s • Fund of Funds • Hedge Funds • Hybrid P oducts • nfrastructure Funds How has the alternatives investments industry changed over the past few years? All signs indicate that it’s changing faster than ever. Increased globalization, more cross-border transactions, significant regulatory scrutiny and change, the convergence of asset classes, and the emerging influence of inst tutional investors have all contributed to the accelerated pace. As a result, the cost and complexity of running an alternative investments organization have risen considerably. Aside from the significant challenge of generating appea ing investment returns, investment managers must navigate trends, implement their organization’s business strategy, and enhance transparency and reporting wh le simu taneously managing costs and risks. • Private Equity Funds • Real Estate Funds • Venture Capi al Funds How can alternative investment managers compete successfully in such an environment? W th the assistance of an experienced professional services firm that can help navigate the challenges and risks of a volatile environment, can compete successfully in such an environment. 4 5 Deep exper ence in alte nat ve investments. KPMG’s A ternative Investment Funds pract ce s compr sed of audit, tax, and advisory professionals w th deep industry exper ence ac oss the broad range of alternat ve nvestment funds, nclud ng hedge funds, priva e equity funds, infrastructure funds, real esta e funds and fund of funds. Throughout the li e cycle of the fund, from formation and capital accumu ation to realization and exit, KPMG’s A ternative Investment Funds pro ess onals have the exper ence to help you deal w th the ssues and cha lenges hat mpact your business. Outstand ng team leadership. KPMG deploys an act vely engaged and seasoned team staffed w th leaders that are pos tioned to prov de real-t me gu dance n an env ronment that demands responsiveness. To ach eve this, our engagement teams are comprised of exper enced resources that bring the strength of the firm’s subject-matter experience to every client. Depth and breadth of services. Our Al ernat ve Investment Funds p ofess ona s serve a broad range of investment managers—from the alternat ve nvestment product groups of dive s fied global financial inst tutions to sta t-up nvestment managers—and funds of vary ng structures— rom private partnersh ps o offshore vehicles and funds registered wi h the U S. Securit es and Exchange Comm ss on (SEC). G obal strength and capabi ities. The depth and breadth of our inte national network gives our al ernative investment clients access to the resources necessary to address their most complex challenges. Around the g obe, KPMG has more than 3,000 p ofess onals n 60 internat onal jur sd ct ons serving investment funds. n the United States, mo e than 1 000 profess ona s, nclud ng over 100 par ners, ocus on serv ng alternat ve investment funds and the r sponsors n major financial cen ers. W th an add tional 900 par ners and pro essionals ocated n the wor d’s commercial hubs, th s global network— 1,900 strong—empowers KPMG to serve our cl ents wherever hey do bus ness. Unriva led f nancial service capabi ities. KPMG’s Al ernative Investment Funds p actice is an ntegral part of the f rm’s Financ al Services (FS) line of bus ness. The FS line of bus ness serves more han 20,000 clients worldwide, including more than a quarter of KPMG’s FORTUNE 1000 clients n the United States. In fact, KPMG has the largest presence in the FS indus ry of a l the major accounting firms. Thus, our A ternative Investment Funds pro ess onals are deeply experienced n the ssues, cha lenges, trends, and risks re evant to FS companies. 1 Life Cycle of a Fund Forma ion & Capital Accumulat on 5 Real zation & Exit 2 Acquisi ion of Investments 3 4 Restructur ng, Ref nancing, & D vesting Report ng on Per o mance & P an Del ve y From formation and capital accumu ation to real zation and exit, KPMG s Alternative nvestment Funds professionals have the exper ence to help you deal with issues and challenges that impact your bus ness. We are confident KPMG LLP is that firm. © 2 12 KPMG LLP a De aware im ted l ab l y p rtn rsh p and he U S member rm of he KPMG ne wo k of in ependent member f rms af l ated wi h KPMG nte nat ona Coopera i e ( KPMG In erna onal”) a Swiss en i y A l r gh s ese ved Pr n ed n the U S A The KPMG name logo and cu t ng th ough omp ex ty” a e eg ste ed rad ma ks or t adem rks of KPMG In ern t onal 25074NSS © 20 2 KPMG LLP a De aware im ted l ab l ty pa tne sh p nd he U S member i m of he KPMG ne wo k of in ependent member f rms af i ated wi h KPMG nte nat ona C opera i e ( KPMG In erna i nal”) a Swiss en i y A l r gh s eser ed Pr n ed n the U S A The KPMG name ogo and cu t ng th ough omp ex ty” a e egi te ed rad ma ks or t adem rks of KPMG In ern t onal 25074NSS 4 | KPMG s Dist nc ive App oach o A ternative Inves ments A Broad-based Approach: Audit, Tax, and Advisory Services No investment firm operates in a vacuum... An investment decision, for instance, might not be made as a result of tax consequences. To help you deal w th this increasingly interconnected financial environment, KPMG has coordinated the capabil ties of our audit, tax, and advisory functions to help ensure your business decisions consider a variety of perspectives, which includes the vantage point of fund and investment managers, investors, and other service providers. As part of this broad-based approach, we can provide you w th dedicated local resources, in key international financial centers and offshore jurisdictions, who are knowledgeable about local regulations and operations, but who are also integral to our international network and who have direct access to resources around the globe. Audit Services Our gu d ng princ p e for audit is s mple: an audi or’s judgment about the financial statements must be grounded n an int mate knowledge of a cl ent’s bus ness, industry, processes, accounting pol c es, vendors, nternal controls, governance, and f nanc al report ng ssues. Th s is an act ve aud t approach, engaging our partners and managers to br ng a marketfocused perspective to craft the most appropriate approach to your engagement and deliver high quality client service. Our audit p ofess ona s bring trad tional audit backgrounds and an array of exper ence, includ ng service wi h leading fund organizations, the SEC, the F nanc al ndustry Regu atory Author ty (FINRA), and asset management organizations. Globally Recognized for Outstanding Service Providing outstanding service to our cl ents is very important to our global team of audit pract tioners. To this end, KPMG is proud to be consistently recogn zed with prestigious awards on an annual basis. Awards won in 2011 Our audit services include: • Manager and fund s atutory audit • Techn cal accounting advice • G obal nvestment Performance Standa ds (GIPS) attestation • A testation of nternal controls and Serv ce Organizat on Con rol reports fo merly SAS 70) • Internal audit services © 2 12 KPMG LLP a De aware im ted l ab l y p rtn rsh p and he U S member rm of he KPMG ne wo k of in ependent member f rms af l ated wi h KPMG nte nat ona Coopera i e ( KPMG In erna onal”) a Swiss en i y A l r gh s ese ved Pr n ed n the U S A The KPMG name logo and cu t ng th ough omp ex ty” a e eg ste ed rad ma ks or t adem rks of KPMG In ern t onal 25074NSS © 20 2 KPMG LLP a De aware im ted l ab l ty pa tne sh p nd he U S member i m of he KPMG ne wo k of in ependent member f rms af i ated wi h KPMG nte nat ona C opera i e ( KPMG In erna i nal”) a Swiss en i y A l r gh s eser ed Pr n ed n the U S A The KPMG name ogo and cu t ng th ough omp ex ty” a e egi te ed rad ma ks or t adem rks of KPMG In ern t onal 25074NSS
  12. 12. White Paper Create annual whitepaper and look for marketing materials for outlook survey. Develop charts and montage images as requested by client. KPMG Forensic Technology Brochure 11 M&A Out ook Su vey | 4 3 | M&A Ou look Survey presented by 2013 M&A Outlook Survey Executives Expect M&A Market to be Active in the Year Ahead Growth Opportunities Motivate Deals Wh ch factors wi l be motivating these deal-makers? Respondents sa d hat the number one reason for mak ng an acqu s tion was to expand their company’s geog aph c reach 20 percent). Other important reasons ncluded PE buyers seeking profitable operations 19 percent), enter ng into a new line of bus ness (17 percen ), and expanding their customer base (15 percent). Several respondents a so noted that sel ers seem more real st c about valuat ons and deal prices had gotten more attractive. One respondent said he thought his company wou d do more deals in 2013 because of “more reasonab e seller expectations” and another noted “very low pr ces.” Primary Deal Motivators kpmg.com Expand geograph c each F nanc al buyer ook ng for prof tab e oper tions and/or ga n on exit En er in o new l nes of bus ness Expand cus omer base Last year saw several blockbuster deals, including Softbank’s $20.1 bi lion bid for a stake in Sprint Nextel and Nest e’s $11.9 bi lion deal for Pf zer’s infant nutr tion unit. However, the midd e-market remained the most active sector. Respondents conf rmed that deal s ze s expected to remain on the sma ler s ze. Seventy-nine percent of respondents said that they expected the r dea s to be valued at $250 mi l on or ess. (By compar son, n last year’s survey, 68 percent of respondents sa d the r deals wou d come in at $250 m llion or ess.) Twelve percent of espondents said the r companies wou d be nvolved in dea s valued between $250 mi l on and $499 mi lion and ess than two percent sa d their companies would be doing deals valued between $1 bi l on and $5 billion. KPMG’s Phil Isom, princ pal and U.S. leader for its Corporate Finance and Restructuring practice sa d the survey results are consistent with what he s seeing in the marketplace. “Midd e market deals continue o be the most active. G ven the smaller valuation ranges, and shareho der base ( requen ly owned and operated by en repreneurs or management team), they are eas er to f nance and get across the f n sh line despite a st ll somewhat unce ta n economy,” he sa d. “ n add tion, many restructuring opportun ties sti l exist n th s segment.” Deal Size Stays Small In terms of which industr es would be most act ve n 2013 and beyond, respondents expected software/ telecommunications/technology to be the most act ve sector (39 percent), fol owed by hea thcare pharmaceut cals (35 percent), energy 31 percent), and financial serv ces (20 percent).3 KPMG’s Moyers agreed that technology and healthcare will continue to be at ractive, especially for PE investors. “The constantly evolving world of technology, and investment opportunit es hat arise as we get more c arity around Obamacare, will create attract ve opportunities in those sec ors,” he said. The vast major ty of respondents (73 percent) expect North America to be the most popular deal dest nat on. Other reg ons where M&A s expected to be obust are Western Europe (28 percen ), Ch na (27 percent), Braz l (20 percent), and Asia, excluding Ch na and Ind a (19 percent).4 Tiemann explained, “Nor h America’s re at ve fiscal health and recovering consumer marke s make t a popular nvestment destinat on. The European debt crisis w ll also create investment opportun ties, especially in the distressed sector. And the growth prospects of the emerging markets make them almost necessary deal locations or firms seeking revenue growth.” Industries with the Most Activity Most Popular Regions Software/ elecommun cat ons/ technology Nor h Ame ica Heal hcare/pharmaceu ica s Energy Western Eu ope Financial se vices China ndus r al products Consumer p oduc s/ ood and beverage Braz l E ect on cs Pro ess onal serv ces e g aw fi ms accoun ing i ms etc ) In roduce new produc s As a (not inc uding China or nd a) Automot ve Dep oy cap tal South Amer ca (not nclud ng B azi ) Transporta ion Less than $250 mi l on Eastern Europe (not includ ng Russ a) Chemica s Enhance nte lec ual proper y $250 m l on to $499 mi l on Re ail India O her Other $500 mi ion to $999 mi l on Med a B ing in house another funct on n he supp y cha n M dd e East Af ica Gove nmen /h gher educat on/ not for p of t 0% 5% 10% 15% 20% 25% $1 bi l on o $5 bi l on 0% 10% 20% 30% Russia 40% 0% 20% 40% 60% 80% 100% Grea er han $5 bi l on 0% 0 P P P A special supp ement to Mergers & Acquisitions P P P P PP 20% 40% 60% 80% Mu tip e responses permit ed Mu tip e responses permit ed P 0 P P P P 9 P PP 9 M&A Ou look Survey | 6 5 | M&A Ou look Survey Corporate Buyers have a Slight Edge Due Diligence Remains Key Although deal-makers were gene a ly optimistic about activity eve s, they did c te several concerns and noted that due diligence remained even more mportant in today’s volati e environment. Almost two th rds (62 percent) of survey respondents noted that they thought deal activity wou d be most inh bi ed by recess onary fea s and a s ow growth environment. Other issues they thought would s ow deal low included uncerta nty su rounding tax code changes (31 percent), conce ns about Europe (23 percent), and regulatory considerations 21 percen ).5 Factors Inhibiting Deal Activity Recessiona y fea s/s ow grow h envi onment Unce ta n y su rounding ax code changes Concerns about European econom c s tua ion Regu atory cons dera ions Avai ab l ty nd or cost of debt f nancing Effect of unemployment on consumer demand Stock pr ce vo ati ty O her 0% 10% 20% 30% 40% 50% 60% 70% P P P P “It is also crucial to analyze tax ssues and implicat ons as pa t of the due dil gence process,” acco ding to L sa Madden, KPMG’s leader of M&A Tax. “Over the last several years, he e has been a large degree of uncertainty concerning tax ssues and buyers need to have a thorough understanding of how d fferent tax outcomes might a fect their dea s and deal s ructures,” she said. The vast major ty of respondents agree: they do consider tax impl cations at the outset of a deal (69 percent). Another 28 percent sa d that tax ssues are cons dered after key deal terms and structures are f nal zed. P When asked wh ch ex t strategy would be preferred by sel ers in 2013, 65 percent of respondents sa d hey thought companies would prefer to se l to a st ateg c buyer. Eighteen percent said they thought sellers would pre er to sell to a f nancial buyer, 13 percent said they thought companies would choose to ref nance or raise debt cap tal, and hree percent sa d that companies would pre er an IPO. Corporates vs. PE Buyers Corpora e buyers Pr vate equ ty buyers t s always nteresting o try to determine who wi l have an edge when seek ng out the most valuable targe s. In light of he responses g ven to p eferred exit strategies, t s not surpr sing that according to 44 percent of respondents, corporate buyers have a slight advantage n the current deal env ronment. Thirty percent sa d they thought PE buyers wou d have the advan age and 17 percent said ne ther wou d have an advantage.8 Corporate buyers would most likely have an advantage because they would have g eater synergy opportunit es and thus be able o pay a higher pr ce n an auct on s tuat on. Nei her wi l have n advantage Don t know 0% 10% 20% 30% 40% Conclusion The last few years have provided the M&A market and the economy in general with many challenges. More certainty around U.S. fiscal and tax policy and movement on the European debt crisis should further so idify consumer confidence and improve global economic prospects. Despite the fact that uncertainty st ll ex sts, dealmakers are cautiously optimistic and the vast majority of them said they will be seeking growth opportunities through acquisitions this year. An improving M&A market should begin to take shape in 2013 and extend into the near future. The rema nder of responden s had no op n on Mul iple esponses pe mitted Mul iple esponses pe mitted Mu tiple responses permi ted P In terms of due diligence, responden s said the r greater challenges were presen ed by the assessment or volatility for future revenue streams (43 percent). Other important cha lenges ncluded assess ng the target’s quality of earn ngs (31 percent), revenue and cost syne gy analys s (25 percent), and ssues surround ng the cultural assessment of the target (21 percent).6 Simi arly, ntegration issues also present s gnificant cha lenges and should be analyzed during the due diligence stage of a deal. The most s gnif cant integrat on ssues for respondents were cultural ssues (38 percent), closely fo lowed by human capital issues (36 percent), operat onal and rat onalization ssues (34 pe cent), and issues ar s ng from ntegrating products and serv ces and accounting systems (both 17 percent).7 L ck of sui ab e oppor unit es 0 P P P P PP 9 P 0 P P P P P P P PP 9 P 50%
  13. 13. Redesign and layout for specialized forensic brochure applied as a template for new materials. KPMG Forensic Technology Brochure 3 12 • Data co lection strategies • Data f ltering and cu l ng strateg es ( ncluding keyword search) • Incorporating review resul s into ongoing collect on and fil ering/cull ng s rategy • Data stratification and sampling • Custodian-based prioritization and sampling • Systems-based pr or tizat on and sampl ng • Ident ficat on of multi-l ngual documen s KPMG helped us with a large e-discovery project in the context of bet-the-company l tigation. Beginning to end, they shined. KPMG’s workflow allowed us to quickly and inexpensively cull terabytes of data into a tight set of documents for case analysis and production. KPMG’s metrics and sampling procedures assured us that we had done so accurately and reliably. And we found KPMG’s proprietary review software—with advanced analytics and machine-assisted review—to be state of the art. More generally, KPMG has emerged as one of the leaders and visionaries in the e-discovery industry. We would not hesitate to work with them again. kpmg.com ELECTRON C DISCOVERY ELECTRONIC DISCOVERY KPMG’s proven workf ows to foster effect veness and productivity nclude: KPMG Enterprise Level Electronic Discovery KPMG Enterpr se Level KPMG Enterprise Level Process, Review and Produce 600 gigabytes in Two Weeks In this matter, KPMG’s c ient elected to move forward w th technology assisted review because they needed immediate access to the most like y re evant documents and did not have t me to perform linear review on the who e data set, which included 600 gigabytes of data from 31 custodians, representing 2 5 mil ion documents. KMPG project managers worked with the cl ent and its law firm to tra n the relevance ranking engine, determ ne statistically appropriate cutoff l nes for document review, identify and select the appropriate sample s ze to test and validate their dec sion to withhold and not rev ew documents that had been categorized as irrelevant. The process started with the law firm’s review team reviewing approximately 100 000 documents in order to train the relevance rank ng engine. Then KPMG ran a l 2.5 mi lion documents through its predictive coding process, analyzing all documents based on the tra ning document set. The results were the relevance ranking appl ed to the documents, w th only the most re evant documents being immed ate y reviewed by the law firm n a l near review process, the middleranked group be ng held in batches for further rev ew, and only a random samp e rom the owest-ranked group reviewed for qual ty assurance. As a result, the c ient and its f rm were able to meet its production deadl ne in only two weeks. The KPMG-managed serv ces approach to elect on c d scovery is premised on a phased me hodo ogy that seeks to reduce the volume of data at each step in the p ocess while demonstrating soundness and defensibility. As such, we generally: Defensibly reducing the document set at each stage reduces the cost of the subsequent stage—and all other downstream stages. The savings can be extraordinary. In a recent matter, KPMG applied ts Techno ogy Assisted Rev ew process to a corpus of hundreds of thousands of documents and was ab e to reduce the overall cost to review the documents from an estimated $447,000 to less than $98 000—a reduction of 78%. Leading Technology enables our process, a lowing us to quickly implement changes that wi l benefit our user base broadly, or to create custom implementations for specific client needs KPMG s committed to providing outstand ng e ectronic discovery too s. In many instances, we have developed ndustry- eading applicat ons to del ver the best poss b e solution to he client need. In other cases, we provide process and technical exce lence around leading third-party tools. Discovery Radar® Co lector KPMG’s D scovery Radar Collec or DRC™) is a targeted co lection application that reduces the amount of ESI co lected during l tigat on and o her matters, wh ch n turn reduces p ocess ng and rev ew costs downstream. It is a se f-conta ned executable application that requires no ins a lation, can be launched f om a network share or thumb drive and can be used by remo e desktop to perform long distance col ection for p eservation or rev ew. Using DRC facilitates co lections of data and documents that are most relevant to a matter. By using his approach, ess data is co lected up front, reduc ng the overa l process ng costs, and review costs. A targeted col ection approach s a so more cost e fective and reduces the risk of collecting data that isn’t relevant to the cu rent matter, but, once preserved, may have to be reta ned f it becomes relevant to another. Data collect on capabil ty includes: • Ema l • Native documents KPMG’s Propr etary Tools Global Evidence Tracking System 4 ® • W k s KPMG has bu lt our Global Evidence T ack ng System (GETS) to track both physical and og cal evidence from co lection through the processing and product on stages. It prov des a consistent and systemat c collation of digital evidence, preservation of processed da a, and documentat on of the chain of custody. It a so del vers integ ated ev dence processing notificat ons and data handl ng specif cations. • Calendar tems GETS ncludes a task history eature that provides a detailed status and history of each item of ev dence— ncluding file counts and time stamps for each stage n the process—for audit, metrics and productivity measurement. The resu t is a transparent view of he corpus of evidence and processes that the corpus s undergo ng. GETS s a cr tical tool in support ng client driven priorities to select he order in which evidence is processed and rev ewed. • Other data sources. • Contacts • Tasks • Attachments • M crosoft SharePoint® • Preserve more than we collect • Collect more than we p ocess • Process more than we ingest nto techno ogical tools • Ingest more than we submit for manual review – Attorney Leading International Law F rm 5 KPMG Enterprise Level KPMG Enterpr se Level ELECTRONIC DISCOVERY ELECTRONIC DISCOVERY Techno ogy Assisted Review/Pred ctive Coding Technology assisted review helps o reduce overall project cost by mak ng human review more accurate and efficient. Using technology can a so help a team get to the most relevant data fas er, streamlining the review, and he p ng to reduce overa l rev ew costs, wh ch a e typ cally the most expensive component of discovery. Discovery Radar® KPMG’s proprietary enterpr se d scovery lifecyc e management appl cation, Discovery Radar, of ers advanced functional ty w thin a single environment el m nating the issues caused by moving data from one platform o another. Rev ew of Documents – Review, Analysis and Production The Discovery Radar rev ew module p ovides fu l-text search ng, fi ter ng and document rev ew capabilities and supports hosted native f le review, hosted image eview n TIFF or PDF format, and a hosted hybr d review that consists of native and TIFF fi e review. KPMG has fully integrated Equ v o>Relevance techno ogy nto its D scovery Radar platform to analyze these arge volumes of data and efficiently rank documents. A elevance ranked rev ew leverages the know edge and experience of a Subject Matter Expert (SME) across the document corpus based on an ite at ve train ng process. The software ranks the relevance of the selected document popu at on based on the SME eviewer’s feedback on samples of documen s, resu ting n efficiencies and mitiga ed risks throughout the l tigat on and nvestigation process. • Pre-filtering by custod an, metadata, fi e type, date range, keywords and de-dupl cation • Tagg ng, redact ng, Bates stamp ng and exporting n document sets • Fu l document rev ew functionality with effic ency too s or both the document rev ew admin strator as we l as nd v dual document rev ewers • Issue coding, annotating, redacting, pr nting, and down oad ng as nat ve f les • Stat stical sampl ng capab l ty throughout the appl cation (early case assessment, quality control, ver ficat on of technology-assisted review resu ts, etc.) All operations a e tracked and subject o D scovery Radar’s robust, customizable report ng on user act ons, productivity, and rev ew management metrics. “KPMG has been positioned by Gartner, Inc., in the Visionaries Quadrant of the analyst organization’s 2012 Magic Quadrant for e-Discovery Software report.” – Gartner Inc Mag c Quadrant for E Discove y Sof ware Debra Logan Shei a Ch lds May 24 2012 Relevance Review Model Subject ma ter expe t ev ews a samp e Staff attorneys con irm result ng relevant documents ® D scovery Radar delivers: • Fu l endorsement and product on capab l ties 6 Review Optimizat on D scovery Radar was bu lt to facil tate the fastest and h ghest quality eview poss b e. Search capabilities include “fuzzy search,” which accommodates for word variances (due to misspe lings or OCR ssues). In addition, a l documents are processed so that various “Re ated Documents” ( .e , attachments, exact dupl cates, near-duplica es, other messages in the thread) can be d splayed as shown here and organized n batches. D scovery Radar’s f lter ng capabil ties a low for qu ckly dentifying documents that are not responsive or relevant. Our clients can easily stratify the corpus of documents by us ng sea ch terms, conversation threads, document similarity groups and concept search. With accelerated reviews cl en s can enhance rev ew quality, enr ch keyword lists, and effectively reduce costs and manage resources by rev ewing ess data. Gartner does not endo se any vendor p oduct or se vice depic ed in its research publ cat ons and does not adv se technology users to select only those vendors with the highest rat ngs Gartner research publ cations cons st of the op n ons of Gartner s research o gan zat on and shou d not be cons rued as sta emen s of fact Gartner disc aims all wa rant es expressed or imp ied wi h respect o th s research ncluding any warran ies of merchantabi ty or f tness for a par icular purpose KPMG has bu lt n attr bute sampling for the discovery process n order to fac litate Techno ogy Assisted Rev ew and pred ct ve coding. Our sampling tools and methodology, wh ch can also be applied n other areas of eview, he p our clients meet search-eff c ency and quality assurance goals, increase productivity, and reduce costs wh le mainta ning or even mproving defens b lity. Contract at o neys perform inal reviews on sma ler set of less relevant documents Low relevance documen s cou d be sampled and inear review costs avoided wi h minimal r sk Audit History and Report ng The D scovery Radar Aud t History feature improves defensibility and transparency by tracking actions performed by reviewers and other users to ndividual documents dur ng the d scovery process. KPMG’s work process procedures to manage document review and electronic discovery are enhanced by the DR Report Writer. With n Report Writer, custom reports can be created o monitor and manage document reviewer metr cs, productivity and document/work product d sposition. KPMG believes in always recommend ng the best tool for our client s part cular set of ci cumstances. In cases where KPMG s proprietary echnology is not the best option, or to suit a cl ent s preferences, KPMG also supports best-of-breed th rd-party too s such as Nuix®, Attenex Patterns®, C earwell®, Re at v ty® and Encase®. “ “We elected to move forward w th technology assisted review because we needed immediate access to the most likely relevant documents and did not have time to perform inear review on the whole data set . It has been and continues to be our experience that when used on the proper type of data, by the appropriate team of professionals, this technology works. You guys made it easy.” “ Brochure --Shareholder, 120-Attorney Law Firm
  14. 14. Interactive PDF Citibank™ Interactive PDF and Print 13 What’s New May 2011 Issue 16 Global Update from lee Waite Table of Contents Section 1: What’s New... across our network Sincere hanks for your participation in this important industry va idation a Market MIleStone announCIng CItI’S 60th branCh We are also very exc ted to te l you about a major milestone the opening of our 60th branch for sub custody in South africa one of the most unique aspects of Ci i is our global p esence our local teams who are now spread across 60 markets pr de themselves in unde standing the intricacies of regulations and market practices and in driving changes that benefit interna ional investors and we are continuing to invest in operations across the Middle east and africa to provide you with access to all of the world’s major fund jurisdictions w th one consistent solution across the investment value chain In the next edi ion of Ma ket access we ll have more insight to share on he changes in his exci ing geography global event Calendar 11 ChangIng regulatory env ronMent Challeng ng buSIneSS env ronMent MakIng Market InforMatIon More SuSta nable Global Expertise with Local Insight 10 emerging Market surveys we received ‘top rated’ votes in 35 markets 9 markets more than in 2009 and we are working hard to de iver better service at every tu n We d ike to thank you all for the feedback you’ve provided on this information channel and are excited to int oduce a new format and delivery for the important information housed in Market access What we heard f om recent dialogue is that the information contained he ein is very valuable to making you more efficient and knowledgeable about changes in he ma ket and we heard that he majority of you wou d l ke the information faster and in a form where you can eas ly pass it to your colleagues In ine with our sustainabi ity strategy to be more eco f iendly we’ve revamped the pub ication to op imize its navigation and speed of de ivery With a quick scan of the contents page you can dec de which markets you want to ead about and click directly to them Sti l ike paper in your hands? If you prefer you can print Market access from your PC to read it during your spare moments We are anxious to hear how you l ke the new format please give us your feedback and sugges ions for fur her improvement as the publication continues to evolve Market Access 3 value added Services for broker Dealers to improve our services We’re delighted by your votes last year which rendered the best resu ts to date for Citi out of he 47 markets that were rated in both Major and Welcome to issue sixteen of Market Access a quarterly look at new solutions and significant market developments from around the world that may impact your business C ti viewpoints artic e 12 as the egulatory envi onment around the wor d continues to evolve we all face challenges to run e ficient operations and satisfy our c ients at the same time Part of our job in satisfying you is to inform you of important ma ket changes and provide insight as to how they may affect your business one of the more ecent and most relevant market changes is fatCa foreign account tax Comp iance act intended to prevent offshore tax evasion by uS persons investing h ough offshore financial accounts or indirec ly hrough ownership of fo eign en ities Planned to come into effect in January 2013 fatCa w ll require foreign financial institu ions hat ho d off shore accounts containing non uS secu ities or bank deposits for uS persons to eport these accounts to he IrS and the risk of non comp iance is a 30% w thho ding tax the implica ions for your operations include enhancements to he account opening process to p operly identify new uS accounts and eviews of existing accounts to document the applicab l ty of fatCa We wi l be sharing more information as t comes available on this important new regulation Section 2: What’s New... In the Markets 14 What s new In the americas 5 C nada Ph l pp nes 18 What s new In europe Middle east and africa We look forwa d to maintaining an open dialogue with you and tapping he knowledge across our network to deliver the latest market developments Please do not hesitate to contact me or your rela ionship Manager should you have any questions or wou d l ke add tional information on he topics highlighted in this edi ion We’re looking forward to seeing some of you at Sibos in September when we’ l also de iver issue seventeen! Chi e nd a What s new In asia Pacific v etn m 22 b lg um f an e net er an s or ugal C ech r pub c eurone t Ma kets Section 3: Country Contacts 27 a MeaSureMent of Sat SfaCt on t’s that time of year again the Major Markets Survey fielded by global Custodian is underway We’ve heard from many of you that this survey p ov des deta led information on your prov de s and is part of the cr teria you use when choosing a partner for Ci i the survey helps as a gu de as to where we can focus efforts lee Wa te Managing Di ector Di ect Custody & Clearing + 2 2 8 6 3247 lee waite@c ti com © 20 1 C tibank n a a l rights reserved C ti and arc Design are service marks of C tigroup Inc used and registered throughout the world 2 Citi Viewpoints: update on latin america latin america con inued its strong momentum and with few exceptions maintains impressive macroeconomic indicators this pos tive outlook is he resu t of high commodity prices along w th prudent economic po icy and pol tical stabi ity which have become the founda ion for long term grow h in he region the rank of investment grade countries in this region has increased significantly including ts latest addition Colombia In 2010 reco d por folio inflows continued into the region surpassing di ect investment fDI) for the fi st time ever Desp te the ongoing debate on how to best manage these inflows egulators in key ma kets have continued to simp ify market entry requirements and ease regulations and reporting equi ements impacting fo eign investors • Country Contacts changes to Decree 2080 including sugges ions that Ci i prov ded to improve the investment conditions of foreign Portfo io Investments in Colombia NEW ZEALAND NIGERIA PAKISTAN PERU Martin Carpenter 612 8225 24 1 Kemi Adewole 2341 279 8573 A jaz Haq 9221 227 3405 Mauricio Schwartzmann 51 (1) 2 5 2 24 martin carpenter@citi com kemi adewole@c ti com aijaz ul haq@c ti com mauricio schwartzmann@citi com PHILIPPINES POLAND PORTUGAL ROMANIA Sari Mortel 632 894 7557 Artur Binkiewicz 48 22 657 7600 Gise le Toloi 35 2 1311 6352 Cristian Agalopol 40 21 203 5215 sari morte @citi com artur binkiewicz@citi com giselle tolo @citi com cristian agalopol@c ti com RUSSIA SINGAPORE SLOVAKIA SPAIN Alexei Fedotov 7 495 642 7665 Matt Brown 65 6328 5006 Jaromir Javurek 4202 3306 1375 Rafael Gonzalez Aller 34 91 538 4238 alexei fedotov@citi com matt1 brown@c ti com jaromir javurek@citi com rafael gonzalezaller@c ti com SRI LANKA SWEDEN SWITZERLAND TAIWAN Mihiri Krishnamoorthy 94 114 794 728 Ola Mjorud 46 87 23 34 67 Louise Krohn 4969 1366 600 Datong K Chang 8862 8726 9220 mihiri krishnamoor hy@c ti com ola mjorud@ci i com louise k ohn@citi com datong chang@c ti com the most important changes that will benefit foreign Investors nclude • e imination of the obliga ion to c eate a foreign Investment Portfo io fund in the market in order to make investments TOPIC WhaT’s neW? Where? WhaT’s The ImPaCT? network expansion • • • Supports c ients’ expansion needs as the world’s cap tal markets continue to globa ize • reinforces C ti’s market leading pos tion w th the largest proprietary network proven solutions unsurpassed local market expertise and scalable infrastructure market Guide launched several enhancements to Ma ket guide Citi’s premier Web channel for de ivering secur ties market information* • foreign investo s that already exist in Colombia as a foreign investment por folio fund wi l have the same rights and respons bi ities under the new accounts that wi l be opened w thout crea ing add tional p ocedures in addition to aDrs whose creation continues to not be regulated by he Central bank gDns are now a type of instrument a lowed for foreign investo s as a regional partner to ts c ients and a ma ket leader Citi has been an active participant in d iving changes to imp ove ma ket efficiency In Ch le the gove nment issued new exempt resolution 36 (terminating former resolution 28) w th regard to fo eign investment this resolution prov ded for several modifications to the terminated resolution 128 the key highlights impacting foreign investors are as fo lows What’s New across our network In the Colombia market significant changes have also been introduced on December 29 2010 the Ministry of finance issued Decree 4800 which mod fies Decree 2080 and Colombia’s legal f amework on foreign investment the new Decree made radical new branch opening expanding our Direct Custody and Clearing network to 60 markets (June 20 1) South africa • Clients w ll be able to make investments not only in secur ties registered at the national Securi ies registry but also in local funds and in interna ional securities egistered in Colombia • foreign Investo s are now a lowed to participate in the repo and reverse repo the structu e of intermediary agents between the investor and the local custodian is recognized such as a global Custodian Sub Custodian and broker Dealer (among other ) Securities lending and Derivatives markets • the limit of uSD 500 000 investment imposed on investors domic led in tax haven • countries is no longer app icable as long as the final investor provides add tional information to the tax autho ity and comm ts to prov de further information when required • foreign investors intending to take control of a Chilean listed company can be • global • Provides c ients with easier access to the latest and most viewed videos from re designed Market guide’s video ga lery to high ight he most recent and most popular video updates from C ti’s experts around the wo ld for c ients C ti’s global experts on key egulatory updates ma ket changes and service developments • Created a new v deo ga lery • Provides c ients with user friendly screens to quickly browse videos and determine ibrary that displays a thumbnail image and short summary for every video available on Ma ket guide for faster access registered under exempt resolu ion 36 however hey must duly info m the tax authority and the relevant authorities about this circumstance • free of payment t ansactions (subject to the co responding taxes) and securi ies lending are perm tted • fX transac ions can be pe formed w th local financial ins itutions that are • expanded customization options to a low • global Custodians or broker Dealers can now perform transac ions in their which videos are of most interest to hem heir “favor tes” a personal co lection of favorite Market gu de content • Provides c ients with quick access to the most personally relevant Market c ients to add videos of their choice to membe s of he fo mal exchange Market own name on beha f of final investors as long as they have a Ch lean tax ID inform the tax agent about this ci cumstance and maintain separate records for heir proprietary investments from those investments performed on beha f of third parties 12 guide v deos 4 30 Designed and developed template for interactive and print. Layouts to be used for quarterly distribution. Is ael
  15. 15. ANNUAL REPORT Amstar Funds Report Created new branding, designed logo and applied look and feel to all new collateral. 14
  16. 16. ANNUAL REPORT 15 Pamrapo Bankcorp, Inc. Designed layouts for annual report. Client chosen selection was taken from concept to completion.
  17. 17. Marketing Kit Samsung Electronics / Professional Products Group Concepted, designed and developed marketing kit from start to completion. Implemented design on all additional collateral. 16
  18. 18. Packaging Design 17 No Nut Nation® T THE PERFEC THE PERFECT BROWNIE BROWNIE 6 individually wrapped Brownies 6 Individually Wrapped Brownies NET WT. 6.3 OZ (179g) 6 Individually Wrapped Brownies NO TREE NUTS. NO PEANUTS. NO WORRIES. THE PERFEC T BR Branding, logo development, design and implementation of full packaging for nut-free brownies and other deserts. OWNIE THE PERFEC T BR 6 Individually Wrapped Brownies NO TREE NUTS. NO PEANUTS. NO WORRIES. Th BROWNIE THE PERFEC T N NO TREE NUTS. NO PEANUTS. NO WORRIES. Serving Size 1 b ownie (75g) Servings Per Conta ner 6 Amount Per Serving Calories from Fat 170 % Daily Value* Total Fat 19g Saturated Fat 11g Trans Fat 0g Cholesterol 80mg Sodium 110mg Total Carbohydrate 38g Die ary Fiber 2g Sugars 29g Prote n 4g Vitam n A 6% Calcium 2% • • 29% 55% 27% 5% 13% 8% THE PERFECT BROWNIE ii F s Co Size 1 brown Milk, Wheat, Soy. rv ng t ins Egg, (75g) t i Our strict allergen protocol includes manufacturing on dedicated nut free equipment in a nut free facility and batch testing for the absence of the o s C re r F t 7 peanut protein for added assurance. 29% www.nonutnation.com V tamin C 0% Iron 6% Not actual size 6 individually wrapped Brownies Serving suggestion Keep frozen and thaw before serving NET WT 15 9 OZ (450g) No Nut Nation LLC 6 Individually Wrapped Brownies NO TREE NUTS. NO PEANUTS. NO WORRIES. No Tree Nuts No Peanuts No Worries No Nut Nation desserts are made with the finest, natural ingredients from carefully selected suppliers with safe, nut free practices. Ingredients: Sugar, Eggs, Semi-sweet Chocolate Chips [Sugar, Chocolate Liquor, Anhydrous Dextrose, Cocoa Butter, Soya Lecithin (Emulsifier), Ground Vanilla Beans], Butter, Unbleached Enriched Wheat Flour, Unsweetened Baking Chocolate (natural chocolate liquor), Vanilla Extract, Salt. *Pe cent Da ly Values a e based on a 2 000 calo ie diet Your da ly values may be higher or lower depending on your calories needs Calories 2 000 2 500 Total Fat Less Than 65g 80g Satu ated Fat Less Than 20g 25g Cholesterol Less Than 300mg 300mg Sodium Less Than 2 400mg 2 400mg Total Carbohydrate 300g 375g Dieta y Fiber 25g 30g Calories per gram Fat 9 • Ca bohydrate 4 • Protein 4 NET WT. 6.3 OZ (179g) 6 Individually Wrapped Brownies NO TREE NUTS. NO PEANUTS. NO WORRIES. The Perfect Brownie Nutrition Facts Calories 310 OWNIE Waldwick, NJ 07463 THE PERFECT BROWNIE 6 individually wrapped Brownies NO TREE NUTS. NO PEANUTS. NO WORRIES.
  19. 19. Powerpoint Presentation Powerpoint concepts to be implemented in full presentation. Logo design and Powerpoint concepts were implemented in full presentation. Remicade® and Global Leadership Presentation 18
  20. 20. Logo / icon Design Corporate Identifiers for Merck 19 I N T E R F A I T H CENTER ON CORPORATE RESPONSIBILITY I N T E R F A I T H CENTER ON COR PO R AT E RESPONSIBILITY Logo concepts and final design for Merck marketing. INTERFAITH CENTER ON CORPORATE RESPONSIBILITY

×